

Keyword index vol. 38

- A_{2A} adenosine receptors, 13, 367, 397
 A₁ adenosine receptor ligands, 801, 983
 A₃ adenosine receptors, 367
 Abraham descriptor, 939
 Acid hydrazide derivatives, 959
 Acidic fuction (variation of), 855
 Acridinic compounds, 19
 Acute toxicity, 27
 Adenine, 199
 Adenosine, 245
 Adenosine receptors antagonists, 397
 Adult respiratory distress syndrome, 421
 Affinity constant, 383
 Aldosterone synthase (CYP11B2), 363
 Alkylating activity, 597
 Alkylation, 1025
 Alkyl-pyrimido[4,5-*d*]pyrimidine, 719
 AM1, 929
 Amidine, 277
 Amiloride, 547
 Aminium salts, 991
 Aminopyridine, 513
 Aminopyrimidine, 513
 Ampicillin, 875
 Analgesic activity, 513
 Angiogenesis, 825
 Annelated xanthines, 397
 Antiangiogenic activity, 179
 Antiarrhythmic activity, 555
 Anti-asthma, 975
 Antibacterial activity, 313, 533, 769, 841, 851, 913, 1001, 1005
 Antibacterial and Antimycobacterial activity, 89
 Antibacterial anticonvulsant agent, 837
 Anticancer activity, 739, 759, 781, 811
 Anticonvulsant activity, 49, 555, 1005
 Antifolate, 719
 Antifungal activity, 75, 613, 1001
 Anti-HCV activity, 959
 Anti-HIV, 913
 Anti-HIV-1 activity, 929
 Anti-inflammatory activity, 27, 157, 297, 313, 621
 Antileishmanial activity, 711
 Antimicrobial activity, 27, 519, 1035
 Anti-*Mycobacterium*, 791
 Antineoplastic activity, 1025
 Antioxidant, 1, 621
 Antiproliferative agents, 109
 Anti protozoal activity, 265, 949
 Antitumour activity, 37, 101, 123, 179, 695, 775, 959
 Antiviral therapy, 413
 Apomorphine derivatives, 501
 Apoptosis, 627
 4A protease, 339
 Aqueous two-phase partitioning, 391
 Arabinofuranosylcytosine, 825
 A-ring modifications, 65
 Artificial membrane, 223
 Arylaldehydethiosemicarbazone, 313
 Arylfurfuraldehyde thiosemicarbazone, 313
 4-Aryloxymethyl coumarins, 297
 Aryl-substituted methyleneaminoxymethyl moiety, 157
 Arylthiourea, 313
Aspergillus fumigatus, 75
 Aspirin derivatives, 441
 Autoschizis, 451
 Azabicyclo[4,1,0]heptane derivative, 277
 Azo dyes, 567
 Azoles, 75
 Bacteriostatic, 519
 Benzimidazole, 473
 4-(2'-Benzo[b] furanyl) coumarins, 297
 Benzopyranyl indole, 459
 1,4-Benzothiazines, 769
 Benzotropolone derivatives, 949
 9-Benzyl-*N*⁶-cycloalkyl-2-phenyladenines, 983
 9-Benzyl-*N*⁶-cycloalkyl-2-phenyl-8-azaadenines, 983
 Benzylnitrates, 581
 Binding assay, 687
 Binding mode, 671
 Binding region, 495
 Bioisosterism, 983
 Biological application, 913
 Biomarker, 729
 Bioscreens, 169
 Bioshuttle, 587
 Bisbenzimidazole, 875
 Bispyridium, 109
 Bis(pyridyl)methanes, 37
 Blood–brain barrier, 223, 391
 Boron neutron capture therapy (BNCT), 587
 Boronophenylalanine (BPA), 587
 Brain penetration, 223
 Brigeheadtriazoles, 533
 Bronchoalveolar lavage, 421
 Butyrophenone, 433
 Cage dimeric 4-aryl-1,4-dihydropyridines, 495
 Calcium channel blockers, 867
 Cancer, 451
 Cancer cells, 253
 Cancer-specific antitumor agents, 991
Candida albicans, 75
 Cannabinoids, 403
 Carbapenems, 751
 Cardiselectivity, 459
Catalyst hypothesis, 703
 CCK₂, 671
 CDK, 525
 CDK2 inhibitory activity, 525
 Cell growth inhibitory activity, 525
 60 cell line, 1025
 Chelating ligands, 875
 Chemoresistance, 319
 Chemosensitizers, 253

- Cholecystokinin, 671
 Choline kinase, 109
 Chronic obstructive pulmonary disease, 421
 Cibacron Blue 3GA, 303
 Circular dichroism, 383
¹³C-NMR, 219
 CNS, 223
 Co-crystal structure, 345
 Combilexines, 189
 CoMFA, 141, 975
 CoMSIA, 975
 Conformational analyses, 351, 433, 459, 567, 703
 Congestive heart failure, 363
 Coordination, 893
 Copper, 893
 Correlation, 233, 939
 Coumarin, 297, 597
 COX-2 inhibitor, 157, 645
 Cycloaddition, 613
 4-Cycloalkylamino-1-benzyl-6-phenyl-1H-1,2,3-triazolo[4,5-c]pyridines, 983
 Cyclolignans, 65, 899
 Cyclooxygenase, 645
 Cyclopropanation, 277
 Cytotoxicity, 65, 169, 179, 189, 473, 597, 627, 633, 899
- Database mining, 427
 Deanol, 1035
 Dementia, 661
 Diaminothieno[2,3-*d*]pyrimidines, 605
 Diastereoisomeric purity, 219
 1,8-Diazaanthraquinone derivatives, 695
 Dibromocarbene, 277
 Diflunisal, 1005
 9,10-Dihydro-9,10-ethano and ethenoanthracene derivatives, 253
 Dihydrofolate reductase, 605, 719
 2',5'-Dihydroxychalcone, 179
 Diphenylhydantoin derivatives, 555
 Dithiolanes, 1
 DMSO, 775
 DNA-binding, 189
 Docking, 157, 413
 Doxorubicin, 695
 3D-QSAR, 433, 975
 Drug delivery, 587
 Drug efflux, 253
 Dual, 645
- E. coli*, 345
 Elastase, 289
 Enaminones, 49
 Endocannabinoid transporter inhibitors, 403
 Endocyclic hydrazines, 949
 Endothelium, 501
 Epilepsy, 661
 Equipotent, 875
 E-ring modifications, 899
 Evaluation, 233
 Excitatory amino acid receptor, 661
 Flavones, 929
 Fluorinated surfactants, 519
 Fluoroquinolone, 1001
 Fotemustine, 319
 Fullerene, 913
 Fungi, 925
 Fuzzy logic, 427
- GABA_A receptor, 447
 Geminis, 519
 Glucose dependent insulin release, 357
 Glucosinolates, 729
 Glutathione, 893
 Glycine site, 661, 855
 G protein, 13
- GRID analysis, 141
 GRIND, 433
 GTN, 581
 Guinea-pig taenia coli, 303
- H-bonding, 345
 7-Hemisuccinylpaclitaxel, 383
 Hemolytic assay, 89
 Hepatitis C, 339
 Herpes simplex virus, 899
 HETCOR, 1005
 Heteroaromatic COX-2 inhibitor, 157
 Hetero Diels–Alder reaction, 949
 Hexamethylpropyleneamine oxime, 219
 Hierarchical cluster analysis, 929
 1*H*-Indole-2,3-diones, 633
 11*H*-Indolo[3.2-*c*]quinoline derivatives, 101
 HIV-1 protease inhibitor, 495
 hollow fiber assay, 1025
 Homology modelling, 413
 1*H*-pyrazoles, 27, 959
 HSA binding, 383
 HT-29, 109
 5-HT_{2A}, 433
 5-HT_{2C}, 433
 Human choline kinase, 109
 Human COX-1 and COX-2 enzymatic activity, 27
 Human intestinal absorption, 233
 Human leucocyte elastase, 421
 Hydantoins, 627
 Hydrazide–hydrazones, 1005
 Hydrazones, 633
- hydrogen bonding, 1015
 Hydrophobicity, 391
 6-Hydroxiimino derivatives, 1025
 11β-Hydroxylase (CYP11B1), 363
 Hyperalgesia, 245
 Hyrazide-hydrazones, 781
- IASys, 383
 Ibuprofen amides, 513
 Imidazo[2,1-*b*][1,3,4]thiadiazoles, 781
 Imidazolidin-2-one, 711
 Imidazolines, 357
 Imidazolinones, 837
 Imidazolylmethylindoles, 75
 Indole derivatives, 855
 Indolizines, 867
 Indolocarbazole, 123
 Indolo[3.2-*c*]quinoline derivative, 109
 Inflammation, 199, 645
 Inhibitor of inducible nitric oxide synthase, 277
 Inhibitory activity of interleukin-5, 537
 Interleukin-5 inhibitor, 537
 Intestinal adsorption, 233
 Inverse agonism, 433
 Iodobenzenediacetate, 533
 Ischemia–reperfusion, 547
 Isoflavonones, 537
 Isothiocyanates, 729
 Isoxazolidine derivatives, 613
- K_{ATP} current, 357
 K_{ATP} opener, 459
 Kinase inhibitors, 123, 525
 Kinetic rate, 939
 K-nearest neighbor, 929

- β -Lactam antibiotics, 751
 LET-effects, 587
 Leukocytes, 289
 Lipopeptide, 351
 Lipophilicity, 391
 5-Lipoxygenase, 645
 Lipoxygenase, 289
 Living animals, 925
L.mexicana, *L.infantum*, 711
 Log P, 391, 883
 lung carcinoma, 883

 Mannich bases, 759
 MAP kinase inhibitors, 811
 Maximal electroshock seizure test, 49
 Mechanism-based, 339
 Melanocortin receptor, 481
 Melanoma, 319
 Mercapturic acids, 729
 Metalloporphyrins, 925
 5-Methyl-2-azabicyclo[4.1.0]heptan-3-imines, 277
 1 β -Methylcarbapenem, 751, 841
 MIC (minimum inhibitory concentration), 89
 Microsomes, 925
 Minor groove binders, 141, 189
 Mitochondrial K_{ATP} , 459
 Molecular diversity, 427
 Molecular docking, 413
 Molecular dynamics, 13
 Molecular mechanics, 141
 Molecular modelling, 141, 413, 447, 459, 597
^{99m}Tc-ligand, 219
 Multidrug resistance, 253
 Muscimol, 447

 Mutagenic activity, 473
 MVD bioassay, 687
 Myocardial fibrosis, 363

 1,8-Naphthyridine, 265
 NHE, 547
N-(2-hydroxy acetophenone) glycinate, 893
 N⁶-hydroxyalkyl-2-phenyl-9-benzyl-8-azaadenines, 801
 Nitric esters, 441
 Nitric oxide, 581
 Nitric-oxide donors, 441
 Nitrososulfamide, 319
 5-Nitrothiophene, 851
 NMDA receptor, 661, 855
 Nociceptin analogues, 687
 Non-peptidic ligands, 481
 Non-steroidal anti-inflammatory drugs, 441, 645
 NS3, 339
 Nuclear transport, 587
 Nucleophilic addition, 729

 Octanol-buffer partitioning, 391
 Ofloxacin, 875
O-Methyl-3,4-diamino-2,3,4,6-tetradeoxy- α -L-lyxopyranoside, 775
 Opportunistic infections, 605
 Optical biosensor, 383
 Oral bioavailability, 427
 Organic nitrates, 441, 581
 1,3,4-oxadiazoles, 959
 Oxaliplatin, 739
 Oxazolone, 837
 Oxidation, 501
 Oxidative stress, 1, 451

 Pain, 661

 Paclitaxel derivative, 383
 PALA, 883
 PAMPA, 223
 Parallel synthesis, 345
 Partial agonist, 481
 P450 (CYP) enzymes, 363
 PDE IV inhibitors, 975
 Peptide synthesis, 687
 Peptidomimetics, 671
 Permeability, 223
 P-glycoprotein, 253
 P-gp inhibitors, 19
 Pharmacophore, 703
 3-Phenyl-4(3*H*)-quinazolinones, 633
 2-phenyl-9-(2-hydroxy-3-alkyl)adenines, 801
 2-phenyl-9-(2-hydroxy-3-alkyl)-8-azaadenines, 801
 2-Phenylnaphthalene-type, 101
 Philanthotoxins, 117
 Phosphodiesterase, 199
 Phosphonic derivatives, 597
 Phosphopantetheine adenyltransferase, 345
 4-PIOL, 447
 Platelets, 1015
 Platinum, 739
 Platinum(II), 473, 627, 775
Pneumocystis carinii, 605
 Pneumonia, 605
 Podophyllotoxin, 65, 899
 Polyamines, 117
 Poly(ethylene glycol), 739
 Polymorphonuclear leukocyte, 421
 Potassium channel, 459
 P2-receptor antagonist, 303
 Principal component analysis, 929
 Prions, 567
 Prodrugs, 825, 883
 Promastigote, 711
 α 1-Protease inhibitor, 421
 Pt-DACH, 739
 Pterin, 719
 Pt(II) complex, 473
 Pt(II) complexes, 627
 Purification, 117
 P2X₁-receptor, 303
 P2Y₁-like-receptor, 303
 Pyrazolo[3,4-*d*]pyrimidines, 525
 Pyridones, 37
 Pyridopyrimidines, 245
 Pyridoquinolines, 19
 Pyridothienopyrimidine, 265
 Pyridothienotriazine, 265
 Pyrimido[2,1-*f*]xanthines, 397

 QSAR analysis, 867, 1035
 Quaternary ammonium chlorides, 1035
 Quinolones, 851
 Quinone, 621
 Quinoxaline-1,4-dioxide, 791

 Radical scavenger, 913
 Radiotracer, 913
 Rat aorta, 501
 Rat intestinal absorption, 233, 939
 Rat vas deferens, 303
 Reactive Blue 2, 303
 Rebeccamycin, 123
 Receptor conformations, 433
 Regioselectivity, 925
 Replicon, 339
 RGD, 825
 RT-PCR, 959

- S*-acyl-3-thiopropyl, 883
- S. aureus*, 351
- Schiff bases, 759
- Schizophrenia, 661
- Selective inhibitors, 363
- Serine protease, 339
- Signal peptidase, 351
- Sodium-proton exchanger, 547
- Solution-phase synthesis, 117
- Sophoricoside, 537
- SpsB, 351
- Stepwise discriminant analysis, 929
- Stereoselectivity, 925
- steroidal oximes and oxime ethers, 1025
- Stroke, 661
- Structural characterization, 991
- Structure, 775
- Structure activity relationships, 49, 169, 253, 855
- Structure-affinity relationship studies, 403
- Substituent effect, 841
- Substituted benzimidazole styryl sulfones, 811
- Substrates, 351, 719
- Sulpha drugs, 837
- sulphonamide, 1015
- Sulphonyl-urea (cyanoguanidine) ligand, 703
- Surfactants, 519
- Synthesis, 89, 613, 851
- Synthetic peptides, 13
- Tamoxifen, 1025
- Telomers, 825
- 1,3,4-thiadiazole, 959
- Thiazoles, 313
- Thiazolo[4,5-*d*]pyrimidines, 27
- Thieno[2,3-*d*]pyrimidin-4-one, 89
- THIP, 447
- thromboxane A₂, 1015
- Thromboxane receptor antagonism, 703
- Thromboxane synthase inhibition, 703
- TNF α , 199
- Topoisomerase II, 695
- Topoisomerase I inhibition, 123, 189
- 2-Tosyliminopyrimidines, 289
- 5,5-*trans*-lactam, 339
- 1,2,4-Triazoles, 759
- 1,2,3-Triazoles, 215
- 1,2,4-triazolin-3-thiones, 959
- Triazolopyridines, 533
- Triazoloquinolines, 533
- Triazolo[4.3-*a*]quinolone, 533
- Triptycene, 621
- Tris, 825
- Trispyridinium, 109
- TSE, 567
- Tuberculosis, 215, 791
- TXA₂, 1015
- Type-4, 199
- Ulcerogenic activity, 513
- Ulcerogenic effect, 27
- α,β -Unsaturated ketones, 169
- Varicella Zoster, 413
- Vasoconstriction, 501
- Vasodilator potency, 581
- Vitamins C and K₃, 451
- Water-solubility, 367
- Xenopus laevis* melanophores, 481
- X-ray structure determination, 339, 459, 555, 775